Ajooni Biotech Q2 Results 2026: PAT ₹1 Cr −45%, Revenue ₹65 Cr
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
- Revenue
- ₹65Cr
- +106% YoY
- +3% QoQ
- Net profit
- ₹1Cr
- −45.2% YoY
- +18.6% QoQ
- Margin
- 3.1%
- −1.6 pp YoY
- +0.5 pp QoQ
Top 10 Food Products companies on management guidance
See the sector's top 10 — free with your mobile number.
Ajooni Biotech Ltd Q2 FY27 key numbers
- Revenue
- Total income from operations for the quarter is Rs. 6,568.49 Lakhs, up from Rs. 3,188.26 Lakhs YoY.
As stated in Ajooni Biotech Ltd's Q2 FY27 results statement · published 13 Nov 2026. Reported figures, not investment advice.
Based on Ajooni Biotech Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
Revenue from operations for the quarter ended 30th September 2026 is Rs. 6,536.95 Lakhs, compared to Rs. 3,173.51 Lakhs in the quarter ended 30th September 2025, indicating a year-on-year increase of. Quarterly EBITDA: Rs. 802 crore, up 20.5% year-on-year.
From Ajooni Biotech Ltd's Q2 FY27 earnings-call transcript · updated 13 Nov 2026.
How did Ajooni Biotech's revenue grow in the September 2026 quarter?
- Revenue from operations for the quarter ended 30th September 2026 is Rs. 6,536.95 Lakhs, compared to Rs. 3,173.51 Lakhs in the quarter ended 30th September 2025, indicating a year-on-year increase of approximately 106%.
- Total income from operations for the quarter is Rs. 6,568.49 Lakhs, up from Rs. 3,188.26 Lakhs YoY.
- The company reported a profit before tax of Rs. 70.52 Lakhs for the quarter compared to Rs. 123.37 Lakhs in the prior year quarter.
What happened to Ajooni Biotech's margins in Q2 FY27?
Quarterly EBITDA: Rs. 802 crore, up 20.5% year-on-year.
Locked: what Ajooni Biotech Ltd said on margins
Also locked on this page: capex, fundraising
Free account, 30 seconds. No card needed.
What capex is Ajooni Biotech planning?
See what Ajooni Biotech Ltd said on capital expenditure plans — free account, 30 seconds.
Top-ranked in Food Products
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Ajooni Biotech raising money or cutting debt?
The cash flow statement (Page 7) shows cash flow from financing activities involving:
Locked: what Ajooni Biotech Ltd said on fundraising
Also locked on this page: margins, capex
Free account, 30 seconds. No card needed.
How big is Ajooni Biotech's order book?
Ajooni Biotech Ltd — Quarterly revenue & net profit
Ajooni Biotech Ltd Q2 FY27 results — key figures
| ₹ Cr | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| Revenue | 65 | 32 | +106% | 63 | +3% |
| Operating profit (EBITDA) | 2 | 2 | +34.7% | 2 | +21% |
| Operating margin | 3.1% | 4.7% | -1.6 pp | 2.6% | +0.5 pp |
| Profit before tax | 1 | 1 | -42.3% | 1 | +9.2% |
| Net profit (PAT) | 1 | 1 | -45.2% | 0 | +18.6% |
| EPS (₹) | 0.02 | 0.08 | -75% | 0.01 | +100% |
Source: Ajooni Biotech Ltd's results filing to NSE (standalone), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹65 Cr, net profit ₹1 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →More Q2 FY27 results in Food Products
Continue your research
Others in Food Products this season
- EID Parry (Q2 FY27)
Sugar Segment Q2 FY27 revenue: ₹486 Cr, up 32% from ₹368 Cr in Q2 FY26; sales volume increased from 118.8k MT to 172.2k MT. Key results statement takeaways from
- The Bombay Burmah (Q2 FY27)
Revenue from operations (consolidated) for the quarter ended 30 September 2026: ₹5,797.81 crores (Page 15). Key results statement takeaways from The Bombay Burm
- Venky's (India) (Q2 FY27)
31.7% increase . Key results statement takeaways from Venkys (India) Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Apex Frozen Food (Q2 FY27)
Q2FY27 Net Revenue: Rs 2,737 Mn, up 15% YoY from Rs 2,383 Mn in Q2FY26. Key investor presentation takeaways from Apex Frozen Foods Ltd's Q2 FY27 investor presen
Potential multibaggers · Q2 FY27
Potential multibaggers in Food Products
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Ajooni Biotech Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Ajooni Biotech Ltd Q2 FY27 results?
Revenue from operations for the quarter ended 30th September 2026 is Rs. 6,536.95 Lakhs, compared to Rs. 3,173.51 Lakhs in the quarter ended 30th September 2025, indicating a year-on-year increase of. Quarterly EBITDA: Rs. 802 crore, up 20.5% year-on-year.
What is Ajooni Biotech Ltd share price analysis?
Ajooni Biotech Ltd currently shows a neutral. The stock trades at a P/E of 14.3 with a market cap of ₹57 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Ajooni Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.